Takeaways from American Society of Hematology (ASH) 2025 Meeting

Posted on: December 30, 2025

Jennifer J. Kiblinger, Scientific Director

The ASH 2025 meeting offered a mix of innovation and ongoing debates, highlighting exciting developments in hemophilia treatment, anticoagulation strategies, and novel approaches to hemostasis.

Some highlights for me:

  • Dr. Senthil Sukumar noted the importance of a proactive approach to patient management in immune-mediated thrombotic thrombocytopenic purpura (iTTP), both in monitoring and treating.
  • Dr. Enrico Di Cera presented groundbreaking work on the structural enzymology of coagulation factors using Cryo-EM to refine the map of Factor V (FV). His findings emphasized the critical role of the B domain in FV activity. The FV-short splice variant, linked to East Texas bleeding disorder, was a focal point for understanding regulatory mechanisms.
  • Dr. Rodney Camire highlighted FV’s underappreciated regulatory functions, demonstrating how thrombin generation assays (TGAs) and targeted cleavage at Arg1545 can modulate anticoagulant activity. His team explored monoclonal antibodies to alter FV/FV-short function, with implications for therapeutic development.
  • Dr. Raja Prince Eladnani discussed BnF-001, a first-in-class siRNA targeting Protein S expression, with potential applications beyond hemophilia to conditions like vWD and FXI deficiency. This approach could reshape treatment strategies for bleeding disorders.
  • Dr. Renu Bhargavi Boyapati compared real-world outcomes of DOACs vs. warfarin therapy in Antiphospholipid Syndrome (aPS). In LAC+ aPS patients, DOACs demonstrated noninferior efficacy (though increased risk of iron deficiency), suggesting DOACs could be an alternative to warfarin in single positive aPS populations. Additionally, Dr. Madhu Bhargavi Chandra showed comparative studies suggesting apixaban may offer a safer alternative to warfarin in APS patients with chronic kidney disease, reducing major bleeding and mortality without increasing thrombotic risk.
  • Dr. Jill Johnson showed research that illustrated the importance of genetic testing in females with Hemophilia A, as FVIII levels alone are poor predictors of bleeding risk in this population. Genotype-positive females can experience excessive bleeding despite normal FVIII levels. This underscores the importance of tailored approaches to bleeding in women.
  • Dr. Steven Lentz and Dr. Cedric Hermans described how Mim8 (Denecimig), a next-generation FVIIIa mimetic, demonstrated strong efficacy in reducing annualized bleeding rates in the FRONTIER2 study, with sustained protection and favorable safety. Weekly or monthly dosing? Yes, please.
  • Dr. Steve Pipe provided news of the HOPE-B trial investigating gene therapy for Hemophilia B (etranacogen dezaparvovec) and the continued advancement toward clinical adoption.
  • Dr. Charlotte Story showed that the disruption of the ADAMTS13–VWF axis was linked to ischemic cerebrovascular disease, reinforcing its role in stroke pathogenesis.
  • Dr. Ashley Brown explained how fibrin sets the stage for wound healing. Platelet-like particles (PLPs) mimic platelet function to induce clotting and retraction, enhancing cell migration and wound healing/tissue repair, showing potential to enhance fibrin scaffolds and support Mesenchymal Stem Cell (MSC)-based therapies.

And of course, one of the cutest highlights – the Puppy Playground! Attendees could snuggle and play with puppies during the breaks.

Attendees sit on the floor at the ASH 2025 Meeting Puppy Playground while several puppies rest and sleep on blankets, creating a calm, comforting space for conference participants.

If you were at ASH this year, what were your highlights? Submit your thoughts here!